Building on critical findings from our research streams, we are initiating new drug discovery programmes. Many of our researchers are engaged in target discovery and target validation research – elucidating molecular pathways that can be manipulated for disease modification.
We undertake early phase clinical trials with a focus on detailed phenotyping of patient responses. Besides work on small molecule and antibody therapies, we have expertise in gene therapy. Further down the drug discovery pipeline we lead a large number of clinical trials in a range of different diseases – from those that affect millions in the UK such as diabetes and heart disease, through to rarer conditions such as Cystic Fibrosis and leukaemia.